Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Intellia Therapeutics (NTLA) over the last 11 years, with Q3 2025 value amounting to -$715000.0.

  • Intellia Therapeutics' Change in Accured Expenses fell 11149.7% to -$715000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$10.3 million, marking a year-over-year decrease of 9504.15%. This contributed to the annual value of -$10.4 million for FY2024, which is 27236.06% down from last year.
  • Intellia Therapeutics' Change in Accured Expenses amounted to -$715000.0 in Q3 2025, which was down 11149.7% from $832000.0 recorded in Q2 2025.
  • Intellia Therapeutics' Change in Accured Expenses' 5-year high stood at $18.4 million during Q4 2021, with a 5-year trough of -$22.4 million in Q1 2024.
  • Moreover, its 5-year median value for Change in Accured Expenses was $3.0 million (2022), whereas its average is $764578.9.
  • The largest annual percentage gain for Intellia Therapeutics' Change in Accured Expenses in the last 5 years was 55232.61% (2021), contrasted with its biggest fall of 269209.04% (2021).
  • Over the past 5 years, Intellia Therapeutics' Change in Accured Expenses (Quarter) stood at $18.4 million in 2021, then plummeted by 83.33% to $3.1 million in 2022, then skyrocketed by 194.01% to $9.0 million in 2023, then plummeted by 56.23% to $4.0 million in 2024, then tumbled by 118.09% to -$715000.0 in 2025.
  • Its Change in Accured Expenses was -$715000.0 in Q3 2025, compared to $832000.0 in Q2 2025 and -$14.4 million in Q1 2025.